Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Parkinson's disease according to standard medical guidelines, with symptoms at a moderate stage (not too mild and not too severe, known as Hoehn and Yahr stages 2–3).
- You have been on a stable Parkinson's medication routine for at least one month, are willing to sign a consent form, and agree not to change your medications during the study and follow-up period.
Who may not be able to join:
- You are currently taking sleeping pills or stimulant drugs.
- You are taking antidepressants, unless you have been on the same antidepressant at a stable dose for more than three months.
- You have a vision problem such as cataracts, glaucoma, or blindness.
- You have significant memory or thinking difficulties (based on a standard cognitive test score below 24).
- You experience hallucinations or have an uncontrolled mental health condition.
- You have a condition that affects your sleep-wake schedule, such as delayed or advanced sleep phase disorder, shift work, or recent jet lag.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chun-Feng Liu, PhD, Second Affiliated Hospital of Soochow University
Phone: +86 512 67783307
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes from baseline in total sleep time(TST) by polysomnography (PSG) at the end of each intervention period; Changes from baseline in sleep efficient by polysomnography (PSG) at the end of each intervention period; Change from baseline in REM sleep without atonia by (RWA) polysomnography (PSG) at the end of each intervention period; Change from baseline in sleep onset latency polysomnography (PSG) at the end of each intervention period; Change from baseline in Periodic Limb Movement during Sleep(PLMS) by polysomnography (PSG) at the end of each intervention period; Changes from baseline in...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.